ArticleJournal of veterinary internal medicine2026
Retrospective cohort study on the development of keratoconjunctivitis sicca in dogs treated with trimethoprim sulfonamide: a VetCompass Australia study.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundKeratoconjunctivitis sicca (KCS) is a common and important eye disease of dogs and has been associated with the administration of trimethoprim sulfonamide (TMS). HYPOTHESIS/
objectivesDetermine the prevalence of KCS after TMS treatment at a population level and describe risk factors for KCS development. ANIMALS: Dogs evaluated in general veterinary practice in Australia with records in VetCompass Australia between 2012 and 2022.
methodsNatural language processing was used to detect dogs treated with TMS and to detect dogs that subsequently developed KCS. Cox proportional hazards modeling was performed to investigate risk factors such as drug dose, duration of treatment, and patient level characteristics (breed, age, sex).
resultsA total of 2243 dogs were treated with TMS during the study period. Four definitive cases of KCS and an additional 35 cases of possible KCS were detected (prevalence 1.8%; 95% confidence interval [CI], 1.3-2.5%). Median duration of TMS treatment was 10 days for both cases (interquartile range [IQR], 7-17 days) and non-cases (IQR, 7-15 days). Median doses were 32 and 33 mg/kg/day for cases and non-cases, respectively. Trimethoprim sulfonamide dose and duration of treatment were not associated with KCS. Some breeds were over-represented and older dogs were more likely to be affected (hazard ratio [HR], 1.076; 95% CI, 1.005-1.152; P = .04). CONCLUSIONS AND CLINICAL IMPORTANCE: Keratoconjunctivitis sicca is rare in dogs treated with TMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.